1-(4-methylphenylsulfonyl)-7-azido-2-heptanol | 1346434-26-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-methylphenylsulfonyl)-7-azido-2-heptanol
• 英文别名: 7-Azido-1-(4-methylphenyl)sulfonylheptan-2-ol；7-azido-1-(4-methylphenyl)sulfonylheptan-2-ol
• CAS: 1346434-26-1
• 化学式: C₁₄H₂₁N₃O₃S
• 分子量: 311.405
• InChiKey: WDUZVCBEJMFULC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  77.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(4-methylphenylsulfonyl)-7-azido-2-heptanol 在 三乙胺 、 三甲基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.08h， 生成 7-[[(4-Methylphenyl)-diphenylmethyl]amino]-1-(4-methylphenyl)sulfonylheptan-2-ol
  参考文献：
  名称：

  [EN] CONJUGATES OF SOMATOSTATIN AND ITS ANALOGS
  [FR] CONJUGUÉS DE SOMATOSTATINE ET DE SES ANALOGUES

  摘要：

  载体和水凝胶的共轭物用于控制生长抑素及其类似物的生物半衰期。

  公开号：

  WO2015061503A1

文献信息

• [EN] HYDROGELS WITH BIODEGRADABLE CROSSLINKING<br/>[FR] HYDROGELS À RÉTICULATION BIODÉGRADABLE
  申请人：PROLYNX LLC

  公开号：WO2013036847A1

  公开（公告）日：2013-03-14

  Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. This invention provides hydrogels that degrade to smaller, soluble components in a non-enzymatic process upon exposure to physiological conditions and to methods to prepare them. The hydrogels are prepared from crosslinking agents that undergo elimination reactions under physiological conditions, thus cleaving the crosslinking agent from the backbone of the hydrogel. The invention also relates to the crosslinking agents themselves and intermediates in forming the hydro gels of the invention. The biodegradable hydro gels prepared according to the methods of the invention may be of use in diverse fields, including biomedical engineering, absorbent materials, and as carriers for drug delivery.

  描述了在适当的pH和温度条件下通过交联化合物裂解的水凝胶。这些水凝胶可用于传递各种药剂，如药物。该发明提供了在暴露于生理条件下会非酶催化降解为较小可溶性组分的水凝胶，以及制备它们的方法。这些水凝胶是由在生理条件下发生消除反应的交联剂制备而成，从而将交联剂从水凝胶的骨架中裂解出来。该发明还涉及交联剂本身以及形成该发明的水凝胶的中间体。根据该发明的方法制备的可生物降解水凝胶可用于各种领域，包括生物医学工程、吸收材料以及作为药物传递的载体。
• [EN] SULFONE LINKERS<br/>[FR] COUPLEURS AU SULFONE
  申请人：PROLYNX LLC

  公开号：WO2013036857A1

  公开（公告）日：2013-03-14

  Sulfone linkers which couple drugs to carriers of various types are described. These linkers permit the release of the drug over time in a controlled manner. The release occurs through beta-elimination, and does not require enzymatic cleavage. Products of the linkers with both drugs and macromolecules and methods of using them are described as well.

  研究描述了将药物与各种载体耦合的砜键连接剂。这些连接剂允许药物以受控方式随时间释放。释放是通过β-消除而发生的，并不需要酶解。还描述了连接剂与药物和大分子的产物以及它们的使用方法。
• HYDROGELS WITH BIODEGRADABLE CROSSLINKING
  申请人：ProLynx LLC

  公开号：US20170312368A1

  公开（公告）日：2017-11-02

  Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

  描述了在适当的pH和温度条件下，由于交联化合物通过消除反应而降解的水凝胶。这些水凝胶可以用于输送各种药剂，如药物。
• CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES
  申请人：Ashley Gary

  公开号：US20130116407A1

  公开（公告）日：2013-05-09

  The invention relates to conjugates of macromolecular carriers and drugs comprising linkers that release the drug or a prodrug through rate-controlled beta-elimination, and methods of making and using the conjugates.

  该发明涉及大分子载体和药物的共轭物，包括通过速率控制的β-消除释放药物或前药的连接剂，以及制备和使用这些共轭物的方法。
• CONTROLLED DRUG RELEASE FROM DENDRIMERS
  申请人：Ashley Gary

  公开号：US20130123461A1

  公开（公告）日：2013-05-16

  The invention relates to compositions that comprise dendrimers useful in medical and veterinary applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the dendrimer through a linkage that releases the drug or a prodrug through controlled beta elimination.

  本发明涉及一种包含树状分子的组合物，该组合物在医疗和兽医应用中有用，能够提供药物的控制释放，例如肽，核酸和小分子。药物通过一个连接与树状分子共价耦合，该连接通过控制的β消除释放药物或前药。